Ting Chen Speaks at PLI’s “Doing Deals 2024: The Art of M&A Transactional Practice” Program
February 29, 2024
On February 28, 2024, Cravath partner Ting S. Chen participated in “Doing Deals 2024: The Art of M&A Transactional Practice,” a program presented by the Practising Law Institute in New York, which focused on the latest trends and developments in the M&A market and featured outside and in‑house lawyers and investment bankers. Ting spoke on a panel entitled “Negotiating the M&A Agreement in the Time of Covid and Beyond,” which reviewed how to mitigate risk in a purchase agreement, the evolution of the Material Adverse Effect clause and interim operating covenants, and Con Ed provisions.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 2006, Stanford Law School
-
A.B., 2003, Harvard CollegePhi Beta Kappa, summa cum laude
- New York
Education
Admitted In
Related News
Deals & Cases
October 17, 2023
Thermo Fisher Scientific’s Acquisition of Olink
On October 17, 2023, Thermo Fisher Scientific Inc. (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”), a leading provider of next generation proteomics solutions, announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share in cash. Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common shares and all of the American Depositary Shares. The transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million. Cravath is representing Thermo Fisher in connection with the transaction.
Deals & Cases
September 14, 2023
Bacardi’s Acquisition of ILEGAL Mezcal
On September 11, 2023, Bacardi Limited (“Bacardi”), the largest privately held international spirits company in the world, announced the completion of a transaction that makes the family‑owned company the sole owner of ILEGAL Mezcal®, a leading super premium artisanal mezcal. Cravath is representing Bacardi in connection with the transaction.
Deals & Cases
May 25, 2023
Illumina’s Proxy Contest Against Carl Icahn
On May 25, 2023, Illumina, a global leader in DNA sequencing and array‑based technologies, announced that Illumina shareholders have voted to elect eight of nine Illumina director nominees to the Board of Directors. Cravath represented Illumina in connection with these matters.
Deals & Cases
August 08, 2022
Global Blood Therapeutics’ $5.4 Billion Acquisition by Pfizer
On August 8, 2022, Global Blood Therapeutics, Inc. (“GBT”), a biopharmaceutical company dedicated to the discovery, development and delivery of life‑changing treatments that provide hope to underserved patient communities, starting with sickle cell disease, and Pfizer Inc. (“Pfizer”) announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash, for a total enterprise value of approximately $5.4 billion, including debt and net of cash acquired. Cravath is representing GBT in connection with the transaction.
